MedWatch

Novo Nordisk executive joins board of Finnish Orion

Maziar Mike Doustdar, executive vice president for international operations at Novo Nordisk, is stepping aboard Finnish pharmaceutical firm Orion Corporation.

Maziar Mike Doustdar, executive vice president for international operations at Novo Nordisk | Photo: Novo Nordisk / PR

On Monday, Maziar Mike Doustdar, executive vice president for international operations at Novo Nordisk, announced on LinkedIn that he is joining the board of directors of Finnish Pharmaceutical firm Orion Corporation.

”I’m certainly excited and looking forward to working with the other members of the board as well as executive team in supporting the challenges that lie ahead and maximizing the opportunities,” Doustdar writes in his post, also expressing his delight over his new role.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs